Dalfampridine NDC 72162-2459

NDC codes

FDA NDC Directory

Product NDC (as listed)72162-2459Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72162-2459Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72162-2459-6	72162245906	60 TABLET, EXTENDED RELEASE in 1 BOTTLE (72162-2459-6)Marketed from Feb 12, 2025

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Dalfampridine
Generic name (nonproprietary): dalfampridine
Active ingredients: Dalfampridine — 10 mg/1
Dosage form: Tablet, Extended release
Route: Oral
Labeler: Bryant Ranch Prepack
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 210158
Marketing start: Mar 21, 2019
Listing expires: Dec 31, 2026
Other FDA classes: Potassium Channel Antagonists (Mechanism)
Identifiers: Product ID 72162-2459_fd48fc9a-fe75-4178-806c-ea935728cc7fSPL ID fd48fc9a-fe75-4178-806c-ea935728cc7fSPL set ID 688eb479-debc-4cfc-a74d-14828c347049RxCUI 897021UNII BH3B64OKL9
Pharmacologic class: Potassium Channel Blocker

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472162245906 followed by a unit qualifier and the quantity

Package 72162-2459-06. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 12, 2025.

Indications (excerpt from the label)

Dalfampridine extended-release tablet is indicated as a treatment to improve walking in adult patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed [see Clinical Studies (14) ]. Dalfampridine extended-release tablet is a potassium channel blocker indicated to improve walking in adult patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed (1, 14) .

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 210158

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 210158
Product	Strength	Form · route	Labeler	Product NDC
Dalfampridine	Dalfampridine 10 mg/1	Tablet, Extended releaseOral	Micro Labs Limited	42571-275